Filings & corporate actions
- 3 NovresultsResults · Q2 FY27 · consolidated and standalone-0.4%NSE
- 12 OctshareholdingShareholding · 30 Sept 2026+0.5%NSE
- 11 AugresultsResults · Q1 FY27 · consolidated and standalone-4.7%NSE
- 17 JulshareholdingShareholding · 30 Jun 20260.0%NSE
- 19 MayresultsResults · Q4 FY26 · consolidated and standalone-5.5%NSE
- 17 AprshareholdingShareholding · 31 Mar 2026+3.3%NSE
- 10 FebresultsResults · Q3 FY26 · consolidated and standalone+8.6%NSE
- 20 JanshareholdingShareholding · 31 Dec 2025-3.8%NSE
Reaction to results · all yearsrose on day 0 in 1 of 4 CSV
| Quarter | Filed | Day 0 | +5D | +20D | Rel vol |
|---|---|---|---|---|---|
| Q2 FY27 | 3 Nov 2026 | -0.4% | +0.9% | — | 3.4× |
| Q1 FY27 | 11 Aug 2026 | -4.7% | -3.0% | +3.0% | 2.6× |
| Q4 FY26 | 19 May 2026 | -5.5% | -6.9% | +11.3% | 2.3× |
| Q3 FY26 | 10 Feb 2026 | +8.6% | +8.6% | +4.5% | 18.4× |
| Average | -0.5% | -0.1% | +6.3% | ||
Close-to-close from the session before the filing could trade. Day 0 is the first session after it.
Growth · Q2 FY27
| CAGR | 2Y | 3Y | 4Y | 5Y | 6Y | 7Y |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Profit | — | — | — | — | — | — |
Key data
Delivery percentage
Over the last 20 sessions NEPHROPLUS settled 48.3% of its traded quantity, which is above average for an NSE equity. Its one-year average is 51.6%, so recent sessions are running 3.3 points lower than usual.
What delivery percentage measuresScan the whole market on delivery
Dividends, deals & holders
Performance returns
| 1D | 1W | 1M | 3M | 6M | 1Y | |
|---|---|---|---|---|---|---|
| Price | +2.16% | +0.73% | +8.86% | -2.72% | +12.02% | — |
Valuation
Ownership
Quarterly results · consolidated
| Q3 FY26 | Q4 FY26 | Q1 FY27 | Q2 FY27 | |
|---|---|---|---|---|
| Revenue (₹ Cr) | 259.7 | 265.6 | 281.8 | 303.4 |
| YoY chg | — | — | — | — |
| Net profit (₹ Cr) | 32.2 | 30.4 | 32.0 | 33.5 |
| YoY chg | — | — | — | — |
| Net margin | 12.4% | 11.4% | 11.3% | 11.1% |
| EPS | 3.35 | 2.96 | 3.11 | 3.25 |
Shareholding over time
By quarter
30 Sept 2026 · promoter 58.31% · public 41.69%- Promoter
- Public and others
- Promoter
- 58.31%
- Public
- 41.69%
- Promoter change
- -5.54 pp
- Filed
- 12 Oct 2026
- FII
- 11.73%
- DII
- 8.11%
- Promoter pledged
- 0.00%
Who the public is
- Mutual funds
- 3.93%
- Insurance
- 0.45%
- FPI
- 11.73%
- Retail ≤ ₹2L
- 6.41%
- HNI > ₹2L
- 2.29%
- NRI
- 0.78%
- Bodies corporate
- 1.79%
- Shareholders
- 56,735
+0.73 pp QoQ
-0.76 pp QoQ
+2.95 pp QoQ
+2.66 pp QoQ
+0.35 pp QoQ
+0.37 pp QoQ
+1.04 pp QoQ
+28.7% QoQ
Major holders
As of 30 Sept 2026| Holder | Type | Holding | Shares |
|---|---|---|---|
| EDORAS INVESTMENT HOLDINGS PTE LTD | Promoter · Corporate | 26.56% | 2.67Cr |
| VIKRAM VUPPALA | Promoter · Individual | 9.41% | 94.58L |
| POLAR CAPITAL FUNDS PLC - HEALTHCARE OPPORTUNITIES | FPI | 8.28% | 83.27L |
| BESSEMER VENTURE PARTNERS TRUST | Promoter · Other | 8.04% | 80.87L |
| INVESTCORP INDIA INVESTMENTS HOLDING LIMITED | Corporate | 6.27% | 63.09L |
| HEALTHCARE PARENT LIMITED | Promoter · Corporate | 4.89% | 49.19L |
| INVESTCORP PRIVATE EQUITY FUND II | Promoter · Other | 4.48% | 45.04L |
| INTERNATIONAL FINANCE CORPORATION | Corporate | 3.07% | 30.90L |
| THE PRUDENTIAL ASSURANCE COMPANY LIMITED | FPI | 1.91% | 19.17L |
| QUADRIA CAPITAL INDIA FUND III | Promoter · Other | 1.76% | 17.70L |
Every promoter-group member, and each public holder above 1%, as filed.
Promoter and public shares of total equity, from the pattern filed each quarter. Institutional, pledge and public-breakdown figures come from the filing's XBRL, which most filings before Sep-2021 lack, so they are absent there rather than zero. Changes are against the previous filing.
52-week highs & lows
Each session the stock traded past its previous 52-week high or low, from NSE's daily report; the previous figure is the record it broke. Prices as published, not split-adjusted.
Bulk & block deals · 24 Sept 2026
CSV| Date | Deal | Client | Quantity | Price | Value |
|---|---|---|---|---|---|
| 24 Sept 2026 | Buy · bulk | POLAR CAPITAL FUNDS PLC-HEALTHCARE OPPORTUNITIES FUND | 25.46L | 705.00 | ₹179.5Cr |
| 24 Sept 2026 | Sell · bulk | EDORAS INVESTMENT HOLDINGS PTE LTD | 8.42L | 710.18 | ₹59.8Cr |
| 24 Sept 2026 | Sell · bulk | EDORAS INVESTMENT HOLDINGS PTE LTD | 8.42L | 705.03 | ₹59.4Cr |
| 24 Sept 2026 | Buy · bulk | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | 8.23L | 705.24 | ₹58.1Cr |
| 24 Sept 2026 | Sell · bulk | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | 8.16L | 710.45 | ₹58.0Cr |
| 17 Dec 2025 | Buy · bulk | POLAR CAPITAL FUNDS PLC-HEALTHCARE OPPORTUNITIES FUND | 34.28L | 481.77 | ₹165.1Cr |
| 17 Dec 2025 | Buy · bulk | POONAWALLA VISION FUND I | 6.10L | 490.05 | ₹29.9Cr |
| 17 Dec 2025 | Buy · bulk | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | 5.70L | 490.00 | ₹27.9Cr |
| 17 Dec 2025 | Sell · bulk | MANSI SHARE AND STOCK BROKING PRIVATE LIMITED | 5.70L | 483.30 | ₹27.5Cr |
| 17 Dec 2025 | Buy · bulk | MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED | 5.34L | 482.75 | ₹25.8Cr |
| 17 Dec 2025 | Sell · bulk | RAJASTHAN GLOBAL SECURITIES PVT LTD | 5.20L | 490.10 | ₹25.5Cr |
| 17 Dec 2025 | Sell · bulk | MARWADI CHANDARANA INTERMEDIARIES BROKERS PRIVATE LIMITED | 4.89L | 477.65 | ₹23.4Cr |
A bulk deal is a client trading over 0.5% of the company’s shares in a day; a block deal is one large trade in the separate block window. Quantities and prices are as NSE published them, not split-adjusted.
Takeover-code disclosures
Filed under SEBI’s takeover regulations when a holding crosses 5% of the company, and again with every 2% it moves after that. Shares and percentages as filed.
Every stock on this session →Short selling, lending & margin
Shares sold short on the day, as brokers reported them to NSE at the close. As reported, not split-adjusted.
Exchange surveillance
No surveillance measure applies to NEPHROPLUS.
Price band: 20% · not in the F&O ban.
From NSE’s daily surveillance, price-band and position-limit files. A stock enters the F&O ban when open interest passes 95% of its market-wide position limit and leaves it below 80%; until then no new positions can be opened. CSV: measures.
Every stock on this session →Financials · quarterly statement
| Q3 FY26 | Q4 FY26A | Q1 FY27 | Q2 FY27 | Trend | |
|---|---|---|---|---|---|
| Revenue from operations | 259.7 | 265.6 | 281.8 | 303.4 | |
| Other income | 3.3 | 11.6 | 7.5 | 8.0 | |
| Total income | 263.0 | 277.2 | 289.2 | 311.4 | |
| Total expenses | 226.7 | 240.9 | 244.6 | 267.1 | |
| └ Finance costs | 6.0 | 3.2 | 2.2 | 3.1 | |
| └ Depreciation | 21.9 | 25.8 | 24.5 | 27.7 | |
| Profit before tax | 36.4 | 36.3 | 44.6 | 44.3 | |
| Tax expense | 4.1 | 2.8 | 9.1 | 6.9 | |
| Net profit | 32.2 | 30.4 | 32.0 | 33.5 | |
| EPS | 3.43 | 3.03 | 3.19 | 3.34 | |
| Net margin | 12.41% | 11.43% | 11.35% | 11.05% | |
| PBT margin | 14.00% | 13.67% | 15.83% | 14.61% | |
| Tax rate | 11.33% | 7.85% | 20.31% | 15.52% |
A audited · R restated by a later filing · negatives in parentheses. EPS and the share count are restated onto the same split-adjusted basis as the price chart, so they can be read against it; every rupee figure is exactly as filed. The balance sheet and cash flow arrive only with the half-year and annual filings, and are in their own section below. Latest filed 3 Nov 2026.
4 quarters on file; a year-on-year comparison needs five.
Balance sheet & cash flow · half-yearly
Balance sheet
| FY26 | H1 FY27 | Trend | |
|---|---|---|---|
| Total assets | 1,470.9 | 1,633.3 | |
| Current assets | 839.2 | 917.1 | |
| └ Cash & equivalents | 123.9 | 213.2 | |
| └ Other bank balances | 131.6 | 31.4 | |
| └ Current investments | 170.6 | 204.8 | |
| └ Trade receivables | 316.9 | 327.5 | |
| └ Inventories | 33.0 | 47.4 | |
| Total equity | 1,116.5 | 1,189.0 | |
| └ Attributable to owners | 1,116.5 | 1,189.0 | |
| └ Non-controlling interest | 0.0 | 0.0 | |
| └ Share capital | 20.1 | 20.1 | |
| Borrowings | 79.7 | 79.5 | |
| └ Current | 34.6 | 79.5 | |
| └ Non-current | 45.1 | 0.0 | |
| Trade payables | 143.0 | 159.6 | |
| Current liabilities | 299.4 | 378.8 | |
| Total liabilities | 354.4 | 444.4 | |
| Net debt | (346.4) | (369.7) | |
| Debt / equity | 0.07 | 0.07 | |
| Current ratio | 2.80 | 2.42 |
Cash flow, year to date
| FY26 | H1 FY27 | Trend | |
|---|---|---|---|
| Operating cash flow | 232.6 | 89.4 | |
| └ Capex | (119.4) | (37.3) | |
| Free cash flow | 113.2 | 52.2 | |
| Investing cash flow | (410.4) | (24.7) | |
| Financing cash flow | 157.1 | 22.4 | |
| └ Dividends paid | 0.0 | 0.0 | |
| └ Buybacks | 0.0 | 0.0 | |
| Net change in cash | (20.7) | 89.3 |
From the half-year and annual results filings: the balance sheet from September 2022, the cash flow from September 2020. Those are when NSE’s XBRL began to carry each statement; earlier filings have it only in the attached PDF. Cash flow columns are year to date, so an H1 column covers April to September and an FY column the full year. Outflows are in parentheses. Net debt is borrowings less cash, bank balances and current investments; for banks, NBFCs and insurers it, debt to equity and the current ratio are left blank because their statements are not built that way.
Announcements & board meetings
As the company filed them with NSE, newest first. Board meetings are dated by the meeting, which is usually a week or more after the intimation.
Every stock on this session →NEPHROPLUS at a glance
- NEPHROPLUS closed at ₹655.8 on 20 Nov 2026, +2.16% on the day.
- Delivery was 43.3% of traded quantity on 20 Nov 2026, the 20th percentile of its own 230 sessions with a reading (20-session average 48.3%, 1-year average 51.6%).
- Market capitalisation is ₹6,595 crore at a trailing P/E of 51.5 (trailing EPS ₹12.74).
- Q2 FY27 results (consolidated, filed 3 Nov 2026): revenue ₹303 crore, net profit ₹34 crore; the price moved -0.4% on the first session after.
- Promoters held 58.31% at 30 Sept 2026, down 5.54 percentage points on the previous filing.
- Q3 FY27 results are expected between 3 Feb 2027 and 18 Feb 2027, going by past filing dates — an estimate, not an announcement.
About
Sector history
- to 5 Oct 2026Healthcare › Healthcare › Healthcare Services › Healthcare Service Provider
- from 5 Oct 2026Index industry · Healthcare
NSE’s own classification, by the snapshot it changed on.
Prices are adjusted for splits and bonuses. Delivery figures come from NSE’s daily reports and are unavailable for older sessions. Sourced from the eod2 dataset, last updated 20 Nov 2026.
More in Healthcare Services
- APAPOLLOHOSPApollo Hospitals Enterprise Limited9,200.00+5.29%
- MAMAXHEALTHMax Healthcare Institute Limited1,081.00+3.88%
- PAPARASHLTHPARASHLTH844.65+1.16%
- FOFORTISFortis Healthcare Limited825.00+1.87%
- SYSYNGENESyngene International Limited451.70+3.28%
- ASASTERDMAster DM Quality Care Limited779.30+5.41%
- MAMANIPALHOSManipal Health Enterprises Limited702.20+0.83%
- LALALPATHLABDr. Lal Path Labs Ltd.2,006.00+2.18%
- THTHYROCAREThyrocare Technologies Limited528.45+4.67%
- ININDGNIndegene Limited657.65+1.90%
- MEMEDANTAGlobal Health Limited1,480.20+0.13%
- NHNHNarayana Hrudayalaya Ltd.1,943.70+3.77%
All Healthcare Services stocks on the NSEAll Healthcare stocks on the NSE